摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-乙氧基-3-(4-硝基苯基)-丙烯酸乙酯 | 515861-32-2

中文名称
2-乙氧基-3-(4-硝基苯基)-丙烯酸乙酯
中文别名
——
英文名称
ethyl 2-ethoxy-3-(4-nitrophenyl)acrylate
英文别名
ethyl p-nitro-2-ethoxycinnamate;Ethyl 2-ethoxy-3-(4-nitrophenyl)prop-2-enoate
2-乙氧基-3-(4-硝基苯基)-丙烯酸乙酯化学式
CAS
515861-32-2
化学式
C13H15NO5
mdl
——
分子量
265.266
InChiKey
OLPIEKHYJZIIEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    81.4
  • 氢给体数:
    0
  • 氢受体数:
    5

SDS

SDS:14588e156cc4285dbe96e31053595b0c
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-乙氧基-3-(4-硝基苯基)-丙烯酸乙酯 在 palladium 10% on activated carbon 甲酸铵 作用下, 以 甲醇 为溶剂, 反应 16.0h, 以75%的产率得到ethyl 2-ethoxy p-amino cinnamate
    参考文献:
    名称:
    Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
    摘要:
    本发明涉及具有化学式(I)的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物,其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
    公开号:
    US20030229083A1
  • 作为产物:
    参考文献:
    名称:
    COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD
    摘要:
    公开号:
    EP1910270B3
点击查看最新优质反应信息

文献信息

  • Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field
    申请人:Naccari Giancarlo
    公开号:US20090048343A1
    公开(公告)日:2009-02-19
    The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
    本发明涉及具有一般式(I)的化合物,其中R1和R2,可以相同也可以不同,选自包括-H或具有1至6个碳原子的直链或支链烷基基团,或者共同形成具有5或6个原子的芳香或脂肪环的群;Y和Z,可以相同也可以不同,选自包括-H,-OH,-COOH,-OR3,-CH(OR3)COOH的群,其中R3选自H,苯基,苄基,-CF3或-CF2CF3,乙烯基,烯丙基和具有1至6个碳原子的直链或支链烷基基团。
  • Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
    申请人:Giuliani International Limited
    公开号:US08153841B2
    公开(公告)日:2012-04-10
    The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
    本发明涉及具有通式(I)的化合物,其中R1和R2可能相同或不同,选自包括-H或具有1至6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体; Y和Z可能相同或不同,选自包括-H,-OH,-COOH,-OR3,-CH(OR3)COOH,其中R3选自H,苯基,苄基,-CF3或-CF2CF3,乙烯基,丙烯基和具有1至6个碳原子的线性或支链烷基。
  • Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field
    申请人:Naccari Giancarlo
    公开号:US20130005813A1
    公开(公告)日:2013-01-03
    The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.
    本发明涉及通式(I)的化合物,其中R1和R2可以相同或不同,选自包括-H或具有1到6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体;Y和Z可以相同或不同,选自包括-H、-OH、-COOH、-OR3、-CH(OR3)COOH的群体,其中R3选自H、苯基、苄基、-CF3或-CF2CF3、乙烯基、丙烯基和具有1到6个碳原子的线性或支链烷基。
  • COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD
    申请人:Nogra Pharma Limited
    公开号:EP1910270B3
    公开(公告)日:2016-05-11
  • Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
    申请人:DR. REDDY'S LABORATORIES LIMITED
    公开号:US20030229083A1
    公开(公告)日:2003-12-11
    The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), 1 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
    本发明涉及具有化学式(I)的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物,其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐